Feasibility Studies of Nebulized SARS-CoV-2 Neutralizing Antibody in Mice and Cynomolgus Monkeys

PURPOSE: Neutralizing antibodies, administrated through intravenous infusion, have shown to be highly efficacious in treating mild and moderate COVID-19 caused by SARS-CoV-2 infection in the lung. However, antibodies do not transport across the plasma-lung barrier efficiently, and up to 100 mg/kg do...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Jilei, Yin, Zhaojuan, Zhang, Xiao, Li, Huimin, Meng, Dan, Liu, Qianqian, Wang, Hongfang, Han, Meng, Suo, Shixiang, Liu, Yan, Hu, Ping, Sun, Chunyun, Li, Jing, Xie, Liangzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322739/
https://www.ncbi.nlm.nih.gov/pubmed/35882740
http://dx.doi.org/10.1007/s11095-022-03340-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322739/
https://www.ncbi.nlm.nih.gov/pubmed/35882740
http://dx.doi.org/10.1007/s11095-022-03340-9

Ejemplares similares